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Introduction
Streptococcus pneumoniae (pneumococcus) is the main etiologic agent of pneumonias and invasive diseases in children and adults (Table 1) . It is estimated that in developing countries, pneumococcus is responsible for over 1 million deaths per year in children younger than 5 years, the majority in developing countries. [1] [2] [3] In spite of pneumonias causing the largest number of deaths, the mucosal diseases caused by pneumococcus are more common, and the use of antibiotics to treat otitis and sinusitis have been associated with the appearance and dissemination of antibiotic resistant strains. [4] [5] [6] [7] Pneumococcal diseases are more common in children younger than 2 years, elderly people, and in certain groups of individuals that present conditions associated with the development of invasive pneumococcal diseases (IPD) ( Table 2) . [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Moreover, they affect poorer populations more seriously, aggravating the situation of these populations even further. 1, 4 In Brazil, the highest rate of incidence of pneumococcal meningitis has been registered in nursing infants younger than 1 year, and bacterial resistance has increased progressively. 6, 7, 11 From 1983 to 2003, the number of cases of meningitis from pneumococcus was 29,600, with 8,554 deaths.
It is estimated that pneumococcus is the main pneumonia agent in almost all age groups. In Brazil, in 2004, the frequency of hospitalization due to pneumonias in children < 5 years was 2,500/100,000, and the mortality rate from respiratory disease reached 25/100,000 in this age group. 11 The number of cases of pneumonia acquired in the community and confirmed by radiological exam in children < 5 years is substantially higher (566/100,000), particularly among children who live in precarious conditions. 4 The importance of pneumococcal diseases and the increase in bacterial resistance have made it essential to develop vaccines to prevent these diseases, since the 23-valent polysaccharide vaccine (PN23), licensed in 1983, is recommended only for people over 2 years of age. 1 The success of conjugate Haemophilus influenzae type b (Hib) vaccines in several countries encouraged the development of new conjugate vaccines against low, in comparison with the benefit obtained from vaccination. 17 Similar results were found in some provinces in Canada, 
Native Americans
Native Americans also presented high incidence of IPD; in a controlled study that included 8,292 Navajo and Apache children, protection given by Pnc7 vaccine was 76.8%, eight cases of IPD having been registered in the control group and two in the vaccinated group. 21 In Alaska, the conjugate vaccine also showed excellent effectiveness. Although the highest impact was observed in native children, mass vaccination was also responsible for the significant reduction in IPD in non-natives and nonvaccinated adults. 22 
Impact of the vaccine on patients with chronic diseases
There are still few data about the impact of Pnc7 vaccine in patients with chronic diseases. In a small randomized and controlled study conducted in the USA, in which children with and without HIV infection were compared, children with asymptomatic infection presented antibody response comparable to that of the non-infected, but due to the small number of children included, it was not possible to assess vaccination effectiveness. 23 
Reduction of morbidity in persons with viral infections
Persons with viral infections are at high risk of presenting with bacterial complications, such as otitis, sinusitis or pneumonia from pneumococcus. [27] [28] [29] In the USA, it was found that after the Pnc7 vaccine was implemented in the routine calendar, there was substantial reduction in the cases of IPD and influenza-like diseases, both in vaccinated children and in adults and the elderly. In this study, it was not possible to know whether the viral infections were milder in the years following vaccination, and for this reason there was lower incidence of IPD, or whether vaccination contributed to the reduction in the respiratory diseases diagnosed as probably having viral etiology. 29 In another study conducted in Africa, however, Pnc9 reduced the diagnoses of pneumonias that were proved to have been caused by virus by 31%, confirming the literature data that superinfection by pneumococcus is very common after viral infections, particularly by influenza virus and respiratory syncytial virus. 27 Impact of Pnc7 vaccine on respiratory tract colonization by S. pneumoniae
Respiratory tract colonization by S. pneumoniae precedes the occurrence of invasive and non-invasive diseases. 30 The prevalence of healthy pneumococcus carriers is higher in children, particularly in those who attend day care centers, and in adults in contact with children. In Brazil, several studies have shown a colonization rate of about 40% in children less than 2 years of age. [31] [32] [33] [34] Conjugate vaccines reduce the pneumococcus colonization rates and consequently the transmission of these bacteria in the community, thus playing a relevant role in herd immunity. This is important, although there is antibiotics. [35] [36] [37] In addition, the vaccinated group received fewer antibiotics than the control group (17% fewer days of antibiotics). 35 The rates of colonization by VST were inversely related to the IgG class antibody concentrations, indicating that collective immunity must be related to the magnitude of the response. 37 As vaccination of children older than 1 year induces more antibody titres against all the VSTs, it is believed that a conjugate vaccine booster dose plays a relevant role in inducing collective immunity. 1, 16 Impact of Pnc7 vaccine on pneumonias
The result of studies that assessed the impact of conjugate vaccine use in respiratory diseases, particularly in more serious lower airway infections, such as pneumonias, are of great relevance to Brazil, bearing in mind that pneumococcus is the main etiologic agent of these infections. Figure 1 shows the results of studies which assessed the impact of conjugate pneumococcus serotypes (PS) and VST vaccines. 16, 21, 24, 25 In a study conducted in the USA (Kaiser Permanent), the protection given against pneumonia with radiological confirmation was higher than 59%, and for clinically diagnosed pneumonias (without radiological confirmation), 11%. 16 It is important to emphasize that clinical and radiological definition of pneumonia is very difficult. 4 Nonetheless, a large part of the pneumococcus isolates in Brazil come from pulmonary infections. [38] [39] [40] Contrary to the findings in the USA, in which the majority of the pneumococcus strains are isolated in patients with bacteremia, in studies coming from Latin America, around 50% of the pneumococci are isolated from persons with pneumonia. Recent data from a collaborative pneumonia surveillance study in Latin America (Caribbean Project) projected a potential protection of around 60% with the conjugate pneumonia vaccine. 41 It is important to draw attention to the studies conducted in Africa demonstrating the effectiveness of conjugate pneumonia vaccine. 24, 25 The Gambia study was randomized, with double-blind control and involved 22,000 children. The protection given by Pnc9 vaccine for radiologically confirmed pneumonia was 27%, and in comparison with the control group, there were 16% fewer deaths in vaccinated children. 25 
Impact of Pnc7 vaccine on replacement by nonvaccination serotypes and other bacteria
Several studies indicate that in vaccinated children, the VSTs that colonize the respiratory tracts are replaced with PS not included in the vaccine, or by other bacteria, such as non-typeable H. influenzae. 17, 18, 26, 36, 37, [42] [43] [44] Although this phenomenon has been evidenced in several studies, the benefits of the use of conjugate vaccines are greater than the risk of infections by PS not included in the vaccine or by other less pathogenic bacteria and with less resistance to antibiotics. The increased prevalence of H.
influenzae strains, producers of beta-lactamases in the airways of vaccinated children is of concern; while some studies indicate that the use of conjugate vaccines reduces the number of AOM episodes, others indicate there could even be an increase in the number of otitis cases, but with less severity in comparison with those caused by S.
pneumoniae. All the data, however, present a reduction in the rate of severe forms of AOM in the vaccinated population. [35] [36] [37] The appearance of serotype 19 A, which over the last 5 years grew in importance among invasive and non-invasive diseases, is an exception to this rule. 43, 44 Of all the ST included in Pnc7 vaccine, the ST 19F is the one that induces least response. At present, it is known that this vaccine does not give cross-protection against ST 19A. 37 The inappropriate use of antibiotics to treat acute respiratory infections is the main factor associated with increased bacterial resistance. 5 
Status of IPD in Brazil and the potential impact of Pnc7 vaccine
In Brazil, after the introduction of Hib vaccine, S.
pneumoniae is the second agent most frequently isolated from bacterial meningitis cases. The rate of incidence of meningitis from pneumococcus in the Brazilian population is around 1 to 1.5 per 100,000 inhabitants. 11 In children under the age of 5 years, the lethality of meningitis from S. pneumoniae is higher than 30%. In the state of São Paulo, over 500 cases of meningitis are recorded every year, [38] [39] [40] and the coefficients of incidence in children under the age of 5 years are higher in comparison with the population, reaching 17 per 100,000 in children under the age of 2 years (Table 4) . 41 In a study with follow-up of 55 children hospitalized in a tertiary hospital in São Paulo, the mortality rate found was 20%; 40% had neurological sequelae and 60% hearing loss after meningitis from S. is higher than 6%, exceeding that found in the USA after Pnc7 vaccine implementation. [38] [39] [40] All over the world, the PS most resistant to antibiotics this age group diagnosed as having pneumonia with bacteremia and/or pleural effusion. In addition to this, it should be pointed out that over 95% of the strains resistant to penicillin are represented in this vaccine. [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] Therefore, it is expected that Pnc7 vaccine implementation could reduce not only the incidence of IPD, but also the dissemination of resistant strains (mainly ST14).
The is much greater, and it is essential to maintain epidemiological surveillance on the most prevalent STs in the various age groups. 8, 9 As the STs most frequently isolated from children with invasive and non-invasive diseases are the ones that present the greatest clonal variation, it is essential to develop new vaccines for preventing pneumococcal diseases. 8, 9 At present, ST 19 A is the one that causes the greatest concern, not only because of being frequently isolated from vaccinated children that present with IPD in the USA, but also due to the increase in the rate of resistance to antimicrobial agents. 8, 9, 43, 44 
Cost-effectiveness of Pnc7 vaccine
At present, the best parameter for analyzing the costs at a cost lower than 18 dollars per dose. 45 In this study, the indirect benefits of vaccination, which apparently were responsible for 2/3 of the drop in the incidence of IPD in the USA, were not taken into account and nor was the Pneumococcal conjugate vaccine Bricks LF & Berezin E impact of vaccination on the reduction of diseases caused by strains resistant to antibiotics. 16, 39 More recent studies conducted in Australia, France, Canada, Germany and the United Kingdom revealed that the cost-benefit ratio of large scale vaccination is much higher, taking into account the impact on non-vaccinated persons. [46] [47] [48] [49] In Australia, a variation in the rate of pneumococcal disease of 297 to 2,000/100,000 children under the age of 2 years was observed, depending on the population analyzed; the cost per year of life saved with the use of Pnc7 vaccine was calculated to be 190,000 Australian dollars, and by DALY, 104,000 Australian dollars. 46 In comparison with other regions of the world, however, the mortality rate from pneumococcal disease is low in Australia. 47 In a study conducted in Gambia (Africa), the calculation was that for 1,000 children vaccinated, one life was saved.
In this scenario, the cost-effectiveness analysis of the vaccine would be even more favorable. 25 Taking into account that the majority of French children under the age of 5 years present at least one additional factor for IPD (prematurity, low birth weight, breastfeeding for a period shorter than 2 months, attending day care centers, precarious social conditions), Pnc7 vaccine was implemented in the routine calendar of France. 47 
